3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
7
Terminated
2
Withdrawn
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
111
Gastro-enteropancreatic neuroendocrine tumor
19
Carcinoma, Neuroendocrine
12
Stomach Neoplasms
11
Pancreatic Neoplasms
10
Neoplasms
10
Breast Neoplasms
10
Pheochromocytoma
9
Carcinoid Tumor
9
Prostatic Neoplasms
8
Paraganglioma
8
Neoplasm Metastasis
8
Carcinoma, Hepatocellular
8
Adenoma, Islet Cell
8
Thyroid Neoplasms
7
Sarcoma
7
Gastrointestinal Neoplasms
7
Esophageal Neoplasms
7
Colorectal Neoplasms
7
Lung Neoplasms
6
Rectal Neoplasms
5
Ovarian Neoplasms
5
Neuroblastoma
5
Melanoma
5
Liver Neoplasms
5
Colonic Neoplasms
5
Anus Neoplasms
5
Uterine Cervical Neoplasms
4
Gastrointestinal Stromal Tumors
4
Cholangiocarcinoma
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Serotonin Syndrome
×
NET
×
Clear all
NCT07087054
2026-04-30
CAREFNDR
Crinetics Pharmaceuticals Inc.
Phase 3
Recruiting
141 enrolled